Product Description
Mechanisms of Action: PDE3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fudan University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Acute Lung Injury|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR2200055129 | N/A |
Recruiting |
Heart Failure, Acute |
2024-10-12 |
|
PETARDS | P4 |
Unknown status |
Respiratory Distress Syndrome, Newborn|Acute Lung Injury|Acute Respiratory Distress Syndrome |
2023-10-01 |